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Abstract
Mycotic keratitis (an infection of the cornea) is an important ocular infection, especially in young male outdoor workers. There are two
frequent presentations: keratitis due to ﬁlamentous fungi (Fusarium, Aspergillus, phaeohyphomycetes and Scedosporium apiospermum are
frequent causes) and keratitis due to yeast-like fungi (Candida albicans and other Candida species). In the former, trauma is usually the sole
predisposing factor, although previous use of corticosteroids and contact lens wear are gaining importance as risk factors; in the latter,
there is usually some systemic or local (ocular) defect. The clinical presentation and clinical features may suggest a diagnosis of mycotic
keratitis; increasingly, in vivo (non-invasive) imaging techniques (confocal microscopy and anterior segment optical coherence tomography)
are also being used for diagnosis. However, microbiological investigations, particularly direct microscopic examination and culture of
corneal scrape or biopsy material, still form the cornerstone of diagnosis. In recent years, the PCR has gained prominence as a diagnostic aid
for mycotic keratitis, being used to complement microbiological methods; more importantly, this molecular method permits rapid speciﬁc
identiﬁcation of the aetiological agent. Although various antifungal compounds have been used for therapy, management of this condition
(particularly if deep lesions occur) continues to be problematic; topical natamycin and, increasingly, voriconazole (given by various routes)
are key therapeutic agents. Therapeutic surgery, such as therapeutic penetrating keratoplasty, is needed when medical therapy fails.
Increased awareness of the importance of this condition is likely to spur future research initiatives.
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Mycotic keratitis (International Nomenclature of Diseases
disease number 2100) is a general term for a mycosis of the
cornea, and can be caused by a wide variety of fungi [1]. This
condition is usually manifested by severe inﬂammation, the
formation of a corneal ulcer, and hypopyon, with the presence
of fungal hyphae within the corneal stroma. Synonyms include
‘keratomycosis’ and ‘oculomycosis’ (in part), but ‘mycotic
keratitis’ is recommended in preference to ‘keratomycosis’ so
as to have similar names for the diseases caused by fungi,
bacteria and viruses [1]. If the fungal species causing the
infection is identiﬁed, a term such as ‘Fusarium keratitis’(or,
more speciﬁcally, ‘keratitis due to Fusarium solani’) is recom-
mended [1].
Epidemiology
Epidemiology refers to the study of the distribution and
determinants of a disease in a given population in a given
period of time. Whereas prevalence is the rate or frequency
with which the disease is found in a group or population
under study at a particular point in time, incidence is the
frequency with which new cases of a disease arise over a
deﬁned period of time [2]. Going strictly by these deﬁni-
tions, there are no published reports on the prevalence of
mycotic keratitis in the community, but there is one study, in
the UK, that has reported on the incidence of mycotic
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keratitis in a community (0.32 (95% CI 0.24–0.44) cases per
million individuals per year) [3]. However, in less strict
usage, modiﬁed for clinical series [2], it is possible to look at
the prevalence of mycotic keratitis among individuals
presenting with keratitis (corneal inﬂammation) to a hospital;
this provides an estimate of the magnitude of the problem.
In this respect, mycotic keratitis may account for more than
50% of all patients with culture-proven microbial keratitis
[4,5], especially in tropical and subtropical environments. In
terms of absolute numbers, this condition apparently occurs
more frequently in developing countries (e.g. China and
India) than in the developed world (e.g. the USA, Australia)
A single institution in Hyderabad (India) reported that 1360
individuals with culture-proven mycotic keratitis were seen
over a period of 10 years and 5 months [6], and another
institution in northern China reported 654 patients with this
condition over a 6-year period [4]. In contrast, mycotic
keratitis was documented in just 56 eyes (56 patients) in
Melbourne (Australia) and in 61 eyes (57 patients) in New
York (USA) over 8-year and 16-year periods, respectively
[7,8].
Although a high incidence of mycotic keratitis might be
expected in countries with similar annual rainfall and
temperature range, this is not always so and incidence also
appears to depend on the extent of urbanization [9]. Mycotic
keratitis associated with the wearing of contact lenses may
also be on the rise [10] A statistically signiﬁcant increase in
the relative frequency of mycotic keratitis during the years
1997 to 2007 was noted in Egypt; this rise was found to
correlate signiﬁcantly with rises in minimum temperature
and the maximum atmospheric humidity in the greater Cairo
area over the same period [11]. A review of the data from
studies on microbial keratitis conducted worldwide noted
that whereas the highest proportion of bacterial corneal
ulcers was reported from studies in North America,
Australia, the Netherlands and Singapore, the highest
proportion of fungal corneal ulcers was reported from
studies in India and Nepal; interestingly, the Spearman
correlation coefﬁcient demonstrated a statistically signiﬁcant
inverse correlation between gross national income and
percentage of fungal isolates in the studies [12]. A study in
Brazil sought to predict the epidemiology of mycotic
keratitis by monitoring the sales distribution of antifungal
eye drops in Brazil; a linear regression model displayed a
signiﬁcant association between reduced relative humidity and
sales of antifungal drugs, which was interpreted to mean a
seasonal distribution of mycotic keratitis, with a higher
incidence during the third quarter of the year (when the
climate is drier and when agricultural activity is more intense
in Brazil) [13].
Types and Aetiological Agents of Mycotic
Keratitis
In terms of occurrence, risk factors and therapeutic approaches,
two basic types of this condition are recognized, namely,
keratitis due to ﬁlamentous fungi and keratitis due to yeast-like
and related fungi (keratitis due to thermally dimorphic fungi has
only rarely been reported). There appears to be a strong
geographical inﬂuence on the occurrence of the different forms
of mycotic keratitis. The proportion of corneal ulcers caused by
ﬁlamentous fungi has shown a tendency to increase towards
tropical latitudes, whereas in more temperate climates, fungal
ulcers appear to be uncommon and to be more frequently
associated with Candida species than ﬁlamentous fungi [14].
Keratitis due to ﬁlamentous fungi
Filamentous fungal keratitis usually occurs in healthy young
males engaged in agricultural or other outdoor work; these
fungi do not penetrate an intact epithelium and invasion is
secondary to trauma. Trauma is the key predisposing factor,
occurring in 40–60% of patients [5,6]; other reported risk
factors include previous ocular surgery, ocular surface disease,
previous use of corticosteroids (either topical or systemic) and
contact lens use [10,15,16]. Interestingly, in one study on
mycotic keratitis, response to antifungal therapy and or
surgery was observed in none of six patients with previous
ocular surgery, two of six patients with previous ocular
trauma, two of six patients with ocular surface disease, all
three patients with contact lens use and six of 16 patients with
previous use of corticosteroids [16]. Traumatizing agents of
plant or animal origin (even dust particles) either directly
implant fungal conidia in the corneal stroma or abrade the
epithelium, permitting fungal invasion [4–6,17,18].
Species of Fusarium, Aspergillus, Curvularia and other pha-
eohyphomycetes, Scedosporium apiospermum and Paecilomyces
are the principal causes of ﬁlamentous fungal keratitis, but
many other species have been implicated [18–21] (Table 1).
Environmental factors (humidity, rainfall, wind) appear to have
a bearing on the occurrence of ﬁlamentous fungal keratitis and
may also determine seasonal variations in the frequency of
isolation of fungi and the fungal species isolated [14]. Along the
Gulf of Mexico, keratitis due to Curvularia spp. appeared to
occur more frequently during the hotter, moister, summer
months, possibly because of an increase in airborne Curvularia
spores during these months [22].
Although Fusarium species have been cultured from soft
contact lenses during use [23], it was still a surprise when,
from mid-2005 to around July 2006, a multi-country outbreak
of contact lens-associated keratitis due to Fusarium species
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occurred because, until that time, ﬁlamentous fungi had been
infrequently linked to contact lens-associated keratitis. Epide-
miological and microbiological studies implicated the use of a
speciﬁc brand of contact lens multipurpose solution in many
patients affected by the outbreak. The high polymer content of
the solution, as well as non-compliance by the patients, was
hypothesized to have facilitated contamination of the solution
by Fusarium strains derived from the local environments of the
patients. [24].
Keratitis due to yeast-like and related fungi
In keratitis due to Candida albicans and related fungi, one or
more ocular (e.g. insufﬁcient tear secretion, defective eyelid
closure) or systemic (e.g. diabetes mellitus, immunosuppres-
sion) conditions predispose to the infection [25]. This form of
mycotic keratitis may also supervene on a pre-existing
epithelial defect due to herpes keratitis or due to abrasions
caused by contaminated contact lenses [25].
Diagnosis of Mycotic Keratitis
If the diagnosis of mycotic keratitis is made within a short time,
it improves the chances of a complete recovery. Obtaining a
detailed clinical history should be followed by a meticulous
search for ocular or systemic defects that may have predis-
posed to the keratitis, because these need to be corrected to
ensure that the condition does not recur. Symptoms resemble
those reported in other forms of keratitis but, possibly, are
more prolonged in duration (5–10 days).
Diagnosis based on clinical presentation
Filamentous fungal keratitis may involve any area of the cornea
and usually exhibits the following features: ﬁrm (sometimes
dry) elevated slough; ‘hyphate’ lines extending beyond the
ulcer edge into the normal cornea; multifocal granular (or
feathery) grey-white ‘satellite’ stromal inﬁltrates (Fig. 1);
‘immune ring’; minimal cellular inﬁltration in the adjacent
stroma; mild iritis [18,26,27]. An elevated ﬁrm slough and
hyphate margins are found in more than 50% of culture-proven
cases [18]. Although every case of ﬁlamentous fungal keratitis
may exhibit some of these basic features, there may be
variations, depending on the aetiological agent. Chronic,
severe ﬁlamentous fungal keratitis may resemble bacterial
suppuration and involve the entire cornea. Keratitis due to
yeast-like fungi (e.g. C. albicans) and related fungi usually
resembles bacterial keratitis, with an overlying epithelial
defect, a more discrete inﬁltrate and slow progression [25].
In a logistic regression model, serrated margins, raised
slough and colour other than yellow were found to be
TABLE 1. Reported aetiological agents in mycotic keratitisa
Genus Species
1. Hyaline ﬁlamentous fungi
Acremonium A. atrogriseum, A. curvum, A. kiliense, A. potronii, A. recifeib,
Acremonium speciesb
Arthrographis A. kalrae
Aspergillus A. clavatus, A. ﬁscherianus, A. ﬂavipes, A. ﬂavus, A glaucus,
A. fumigatus, A. janusb, A. niger, A. terreus, A. nidulansb,
A. oryzae, A. wentiib
Beauveria B bassiana
Cephaliophora C. irregularis
Chrysonilia C. sitophilab (formerly Neurospora sitophila)
Chrysosporium C. parvumb
Cylindrocarpon C. lichenicola (C. tonkinense)
Diplosporium Diplosporium speciesb
Engyodontium E. alba (formerly Beauveria alba)
Epidermophyton Epidermophyton speciesb
Fusarium F. aquaeductum, F. dimerum, F. oxysporum, F. solani,
F. verticilloides (F. moniliforme), F. nivaleb, F. subglutinans,
F. ventricosum
Glenospora G. graphiib
Metarhizium M. anisopliae
Microsporum Microsporum speciesb, M. canis
Myrathecum Myrathecum speciesb
Ovadendron O. sulphureo-ochraceum
Paecilomyces P. farcinosus, P. lilacinus, P. variotii
Penicillium P. citrinum, P. expansum
Rhizoctonia Rhizoctonia species
Sarcopodium S. oculorum
Scedosporium S. apiospermum (reported as Pseudallescheria boydii;
previously Allescheria boydii, Petriellidium boydii,
Monosporium apiospermum)
Scopulariopsis S. brevicaulis
Tritirachium T. oryzae
Ustilago Ustilago speciesb
Verticillium V. searraeb, Verticillium species
2. Phaeohyphomycetes
Alternaria A. alternata, A. infectoriab, Alternaria spp.b
Aureobasidium A. pullulansb
Bipolaris B. hawaiiensis, B. spicifera (formerly Drechslera)
Cladosporium C. cladosporioidesb
Curvularia C. brachyspora, C. geniculata, C. lunata, C. pallescens,
C. senegalensis, C. verruculosab
Dichotomophthoropsis D. nymphearum, D. portulacae
Doratomyces D. stemonitis
Exophiala E. jeanselmei var. dermatitidis, E. jeanselmei var. jeanselmei
Exserohilum E. rostratum, E. longirostratum
Fonsecaea F. pedrosoi
Lecytophora L. mutabilisb
Phaeoisaria P. clematitidis
Phaeotrichoconis P. crotalariae
Phialophora P. bubakii, P. verrucosa
Tetraploa T. aristata
3. Phaeoid Sphaerosidales
Colletotrichum C. capsicib, C. coccodesb, C. dematiumb, C. graminicola,
C. gloenosporioides, Colletotrichum state of
Glomerulla cingulata
Lasiodiplodia L. theobromae
Microsphaeropsis M. olivaceab
Phoma P. oculo-hominisb, Phoma species
Sphaeropsis S. subglobosa
4. Yeast and yeast-like fungi
Candida C. albicans, C. famata, C. glabratab, C. guilliermondii,
C. krusei, C. parapsilosis, C. tropicalisb
Cryptococcus C. laurentii, C. neoformansb
Geotrichum G. candidumb
Malassezia M. furfurb
Rhodotorula R. glutinisb,R. rubrab, Rhodotorula species
Rhodosporidum R. toruloidesb
5. Dimorphic fungi
Blastomyces B. dermatitidis
Coccidioides C. immitis
Paracoccidioides P. brasiliensis
Sporothrix S. schenckii
6. Other fungi
Absidia A. corymbifera
Chlamydoabsidia C. padenii
Pythium P. insidiosum
Ulocladium U. atrum
Scytalidium Scytalidium sp.
Blastoschizomyces B. capitatus
7. Newly reported agents
Aspergillus viridinutans [19]
Candida fermentati [20]
Thelavia subthermophilia [21]
aModiﬁed from ref [18].
bKey to Uncertain: 1 = not listed in MedLine; 2 = deemed questionable by
McGinnis [69]; 3 = details of identiﬁcation inadequate; 4 = morphology in tissue
not consistent with the fungus isolated. Paecilomyces variotii + = initially identiﬁed
as Paecilomyces viridis.
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independently associated with mycotic keratitis; the probability
of fungal infection, 63% if one clinical feature occurred,
increased to 83% if all three features occurred [28]. In a recent
study [29], clinicians were able to correctly differentiate a
bacterial aetiology from a fungal aetiology 66% of the time, but
the Gram stain, genus and species were accurately predicted
less frequently (46%, 25% and 10% of the time, respectively).
The presence of an irregular/feathery border was associated
with mycotic keratitis, whereas a wreath inﬁltrate or an
epithelial plaque was associated with bacterial keratitis [29].
Hence, although certain clinical signs of infectious keratitis may
be associated with a bacterial or fungal aetiology, appropriate
microbiological tests should be performed at presentation
wherever possible [28–30].
In vivo diagnosis of mycotic keratitis
Non-invasive techniques are being increasingly used for ‘real-
time’ detection of the aetiological agent in patients presenting
with suspected microbial keratitis. Non-invasive methods of
diagnosis include confocal microscopy [31–34], and anterior
segment optical coherence tomography [33,35].
The confocal microscope allows in vivo examination of the
cornea. First-generation confocal microscopes have given way
to more advanced conﬁgurations, such as the advanced
tandem scanning confocal microscope and the Heidelberg
Retina Tomograph II-Rostock Cornea Module (HRTII-RCM).
Recently, HRTII-RCM in vivo confocal microscopy aided the
diagnosis of a fungal aetiology in a patient with keratitis due to
Colletotrichum gloeosporioides, with many septate, hyphae-like
interlocking and branching white lines being visible in the area
of the inﬁltrate [31]; confocal microscopy has been used
similarly in a patient with Cylindrocarpon lichenicola keratitis
[32]. The HRTII-RCM was also recently used to demonstrate
sub-basal corneal nerve alterations (reduced total corneal
nerve lengths and counts, and number of main nerve trunks
and nerve branching) in patients with acute Acanthamoeba
keratitis and mycotic keratitis (compared with normal controls
and patients with herpetic keratitis [34]. Spectral domain
anterior segment optical coherence tomography of 20 eyes (20
patients) with proven fungal or bacterial keratitis (including 12
eyes with culture-proven Aspergillus spp. keratitis) revealed
that mycotic keratitis presented in two unique patterns,
namely, early localized and diffuse necrotic stromal cystic
spaces [35].
In addition to diagnosis, in vivo confocal microscopy and
anterior segment optical coherence tomography may also be
used to monitor the response of mycotic keratitis to
treatment. After 1 month of antifungal therapy to a patient
with keratitis due to Alternaria alternata [33], confocal micros-
copy demonstrated a signiﬁcant reduction in inﬂammatory
cells and the presence of hyper-reﬂective scar-like tissue and
absence of branching hyphal inﬁltrates in the affected cornea;
optical coherence tomography also documented the healing
process and the complete recovery of the central and
peripheral stromal thickness of the affected cornea [33].
The use of confocal microscopy as a diagnostic aid in
microbial keratitis was recently evaluated, with conﬂicting
viewpoints. Using a positive tissue diagnosis as the reference
standard, the authors of one study did not recommend stand-
alone use of confocal microscopy for the diagnosis of microbial
keratitis [36]. Conversely, when conventional microbiology
ﬁndings were used as the gold standard, the authors of another
study concluded that confocal microscopy provides accurate
and reliable diagnosis in mycotic keratitis, particularly when the
corneal inﬁltrate is deep-seated or patients are on treatment
or when microbial keratitis develops after intracorneal
FIG. 1. Keratitis due to Fusarium solani; the irregular edges of the
corneal lesion are prominent.
FIG. 2. Growth of a ﬁlamentous fungus on the ‘C’-streaks of corneal
scrape material made on a culture plate of Sabouraud glucose–
neopeptone agar (after 48 h incubation at 30°C).
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implants [37]. These imaging facilities are valuable in regions
where cost is no constraint to the investigation of infectious
keratitis.
In vitro diagnosis using conventional microbiological methods
Wherever possible, microbiological investigations should be
performed in patients presenting with suspected microbial
keratitis [14,38]. Material is collected using a corneal spatula or
blade, which is used to scrape the base and edges of the
ulcerated part of the cornea several times. Material collected
in one scraping is used to inoculate culture plates and material
collected in an additional scraping is used to prepare smears or
mounts for direct microscopic examination (the spatula can be
ﬂamed after use and cooled before using again; a set of blades
can be used for one patient). Corneal biopsy may have to be
performed where scrapings yield negative results; aqueous
humour may also have to be obtained from the anterior
chamber. Corneal material is usually inoculated on culture
plates in the form of multiple ‘C’s (Fig. 2); only growth on the
‘C’-streaks is deemed signiﬁcant [38]. Two agar media that
should be used are blood agar (incubated at 37°C) and
Sabouraud glucose–neopeptone agar (incubated at 22–25°C);
additional media can be used if warranted [14,38]. In addition
to the solid media, it may be useful to use a liquid medium,
such as brain–heart infusion broth, containing an antibacterial
drug to suppress bacterial growth; however, not all investiga-
tors agree on this point [14,39]. An incubation temperature of
30°C and the use of liquid-shake cultures may also help in
isolation of ocular fungi. Fungal growth usually occurs within
3–4 days (Fig. 2) but culture media may require incubation for
up to 4–6 weeks. Growth in culture is deemed signiﬁcant if the
same growth is obtained (i) on more than one occasion, (ii) on
the ‘C’ streaks on more than one culture medium, or (iii) on
one solid or in one liquid medium with direct microscopy of
corneal material revealing the presence of fungal hyphae or
yeast cells [14].
TABLE 2. Techniques for detection of fungi by direct microscopy
Method Advantages Disadvantages
1. Potassium-hydroxide
(KOH) mount
a. Single-step, Inexpensive simple method.
b. 86% positivity in a series of Fusarium keratitis
c. Oil immersion magniﬁcation not required
a. Artefacts are common
b. Corneal cells do not swell to produce transparent preparations
2. Gram-staining a. Stains Candida blastospores and pseudohyphae
b. Stains hyphae of fungi
c. Bacteria stained and differentiated
d. Preparation can be restained with
methenamine silver
e. Takes 5 min to perform
a. May stain fungal hyphal cytoplasm irregularly or not at all in some cases
b. Stains ﬁbrous protein, causing opacity
c. False-positive artefacts common
d. Crystal violet precipitation may obscure detail and cause confusion
3. Giemsa staining a. Differential staining of tissue and cellular elements
b. Stains yeast cells and hyphae
c. Stains chlamydiae, viral inclusions and protozoa
a. Disadvantages similar to Gram stain
b. Tissue cells stain, forming opaque area where smear is thick
c. False-positive artefacts common
d. Buffer and working solutions need careful preparation
e. Staining time of 60 min
4. Lactophenol cotton blue
staining. Sensitivity: 78%
a. Stain easily available with shelf-life of 1 year
b. Rapid, simple, inexpensive one-step method
c. Important ocular fungi can be seen and identiﬁed
d. Wet mount is a semi-permanent preparation that
can be kept for years
e. Acanthamoeba can be detected
a. No digestion of tissue
b. Unusual fungi may escape detection
c. Contrast between fungi and background material may
sometimes be insufﬁcient
5. Methenamine silver
staining (modiﬁed)
a. Stains fungal cell wall clearly; no interference f
rom background
b. Positives more frequent and reliable than
in methods 1–6
c. Negatives more reliable
a. Excessive deposit of silver may obscure cell wall and septa
b. Stains cellular debris and melanin
c. Gelatin-coated slides needed
d. Controls needed; reagents and procedure need standardization
e. Takes 60 min to perform
6. Calcoﬂuor white (CFW)
Fluorescent dye with high afﬁnity for
polysaccharides, such as fungal cell
walls. This dye is used to detect fungi
in corneal scrapings and in aqueous
and vitreous samples .
a. Excellent sensitivity and good speciﬁcity
b. Detects yeast blastoconidia and hyphae of
ﬁlamentous fungi
c. Material from KOH mount can be used for
subsequent CFW staining
a. Not all fungi are adequately stained
b. Ultraviolet microscope needed
c. Corneal collagen stained, which may cause confusion with the hyphae
of ﬁlamentous fungi
d. Reagents and procedure need standardization and expertise
Modiﬁed from Ref [18]
FIG. 3. Wet ﬁlm of corneal scrape material stained with lactophenol
cotton blue, demonstrating the presence of septate hyaline fungal
hyphae (9 400 magniﬁcation).
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Direct microscopic examination of corneal scrapings per-
mits a rapid presumptive diagnosis of mycotic keratitis; the
techniques used have several advantages and disadvantages
[6,38–41] (Table 2). A suggested set of smears for direct
microscopic detection of fungal structures in corneal material
would be: a wet preparation (potassium hydroxide or
lactophenol cotton blue) (Fig. 3); a Gram-stained smear
(Fig. 4); a smear for staining by special fungal stains (Giemsa,
periodic acid Schiff, Gomori methenamine silver stain, calco-
ﬂuor white). The corneal material should be spread out as
thinly as possible on the slides so as to facilitate visualization of
the fungal hyphae or yeast cells (Fig. 3,4).
In vitro diagnosis using molecular tools
Conventional microbiological methods used for diagnosis of
mycotic keratitis suffer from inherent drawbacks [38,39]. If
fungal hyphae or yeast cells are detected by direct micro-
scopic examination of corneal material, a rapid presumptive
diagnosis of mycotic keratitis can be made. However, an
inexperienced observer may not be able to detect these fungal
structures; more importantly, it is rarely possible to accurately
identify the fungal genus and species involved [39]. Culture of
corneal material overcomes this limitation of direct micro-
scopic examination; however, a positive result (growth in
culture or speciﬁc identiﬁcation of the fungus isolated) usually
requires a minimum of 48–72 h, and some expertise is
required for precise identiﬁcation of the fungal species
isolated [39]. These limitations have led to the evaluation of
molecular methods, speciﬁcally PCR, as a diagnostic tool for
mycotic keratitis. A recent paper [42] elegantly summarizes
the key features of the more than 25 reports in the literature
(from 1996 to 2011) that evaluated PCR as a diagnostic tool
for mycotic keratitis.
PCR is an ideal diagnostic method for mycotic keratitis
because only a small quantity of sample (corneal scrape or
corneal biopsy material) is required to perform the test.
While the cutinase gene was the target in the ﬁrst report in
1996, nearly all the other studies targeted the fungal
ribosomal DNA regions, such as 18S rRNA, 28S rRNA and
internal transcribed spacer regions. Many of the reported
studies have sought to detect fungal DNA in the corneal
sample by PCR-based ampliﬁcation using universal (panfungal)
primers or more speciﬁc primers, followed by identiﬁcation
of the fungus by sequencing of the ampliﬁed fungal DNA;
other studies have reported molecular identiﬁcation of fungi
isolated in culture from corneal scrapings [42]. The biggest
advantage reported is the speed at which a diagnosis of
mycotic keratitis can be made [43,44] and, perhaps more
importantly, accurate species identiﬁcation can be achieved;
this has led certain investigators to advocate the use of PCR
as the reference standard for diagnosis of mycotic keratitis
[42]. On the other hand, a careful evaluation of previous
studies reveals good agreement between the results obtained
using conventional tests and those obtained using PCR [44].
Moreover, one set of investigators [45] cautioned against the
routine everyday use of the technique because non-patho-
genic microorganisms could conceivably be ampliﬁed, therein
confusing the diagnosis. PCR cannot be used to monitor the
response of a patient with mycotic keratitis to antifungal
therapy because it is not possible to differentiate viable from
non-viable fungi. Performing the PCR for the diagnosis of
mycotic keratitis may be more expensive than using conven-
tional microbiological methods. Hence, PCR may possibly be
reserved for diagnosis of mycotic keratitis in patients in
whom conventional tests do not yield positive results.
Probably, in the context of mycotic keratitis, the most
important use of the PCR is in permitting the rapid
identiﬁcation of the infecting fungal strain, because routine
morphological identiﬁcation may not sufﬁce to identify certain
species of Fusarium and of species previously unreported as
causes of mycotic keratitis [19–21,39].
Management
Keratitis due to ﬁlamentous fungi continues to be difﬁcult to
treat despite the use of topical and systemic antifungal agents
and adjuvant surgery, such as corneal transplantation. A recent
Cochrane Database systematic review of medical interventions
for mycotic keratitis (an update of a review in 2005) analysed
nine randomised controlled trials involving 568 participants
who were randomized to various comparisons (including 1%
topical itraconazole versus 1% topical itraconazole and oral
FIG. 4. Smear of corneal scrape material stained by the Gram
method, demonstrating the presence of septate hyaline fungal hyphae
(9 1000 magniﬁcation).
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itraconazole, voriconazole 1% versus natamycin 5%). It was
concluded that, based on the available literature, there is no
evidence to suggest that any particular drug, or combination of
drugs, is more effective than any other in the management of
mycotic keratitis; the trials included in this review were found
to be of variable quality and were generally underpowered [46]
Mycotic keratitis is managed by medical or surgical means.
Medical therapy consists of non-speciﬁc measures and the use
of speciﬁc antifungal agents. Cycloplegics are used to relieve
the iridocyclitis that usually accompanies mycotic keratitis;
broad-spectrum antibacterial agents may be needed to combat
secondary bacterial infection.
In vitro antifungal susceptibility testing
Determination of the pattern of susceptibility of a fungal
isolate from keratitis to different antifungal agents by an agar
dilution [47] or broth dilution [48] method may aid rational
speciﬁc antifungal therapy, but most laboratories do not
routinely perform such tests because the methods in use
are diverse. Using an agar dilution method for antifungal
susceptibility testing, pre-treatment in vitro susceptibility data
were found to correctly predict clinical responses in 43% of
clinical cases of Aspergillus keratitis and in 37% of cases of
Fusarium keratitis [47]; however, oral itraconazole therapy
was used to treat patients in this study. In a more recent
study that determined the MICs of natamycin and vorico-
nazole on isolates from fungal keratitis, a higher MIC was
signiﬁcantly associated with an increased likelihood of
perforation; however, there was no signiﬁcant association
between MIC and 3-week or 3-month visual acuity or
between MIC and 3-week or 3-month inﬁltrate/scar size
[48]. The real value of in vitro antifungal susceptibility testing
in mycotic keratitis lies, perhaps, not in predicting responses
in individual cases, but in providing important baseline data
on the spectrum of activity of antifungal compounds against
ocular fungal isolates.
Medical therapy of fungal keratitis
To treat mycotic keratitis effectively, a drug must be non-
irritating and non-toxic in the eye, must penetrate the eye well
and have a high level of antifungal activity against at least one
signiﬁcant ocular pathogen. Antifungal agents that are useful in
the treatment of mycotic keratitis include [16,17,38,49–53]:
 Topical natamycin (5%), econazole (1%), amphotericin B
(0.15–0.3%), ﬂucytosine (1%), clotrimazole (1%), miconazole
(1%), ketoconazole (1–2%), itraconazole (1%), ﬂuconazole
(1%), voriconazole (1–2%) and caspofungin (0.5%);
 Subconjunctival miconazole (10 mg in 0.5 mL) and ﬂuconaz-
ole (0.5–1.0 mL of a 2% solution);
 Intravenous amphotericin B and miconazole (600–1200 mg/
day).
 Oral ketoconazole (200–600 mg/day); itraconazole (100–
200 mg/day); ﬂuconazole (50–200 mg/day) and voriconazole
(400 mg/day);
 Intrastromal injection of voriconazole and amphotericin B
(5 mg per 0.1 mL);
 Intracameral voriconazole (50 lg/0.1 mL);
 Intravitreal amphotericin B, ﬂuconazole and voriconazole
More details are provided in Table 3. As all the available
antifungal agents only inhibit growth of the fungus, and the host
defence mechanisms must eradicate the organism, treatment is
usually prolonged.
An antifungal agent chosen for therapy of mycotic keratitis
should be easily available. Treatment can be commenced on the
basis of direct microscopy ﬁndings alone if these are unequiv-
ocal and consistent with the clinical evaluation; otherwise,
therapy should be withheld while awaiting the results of
culture. Topical natamycin (5%) is usually chosen as initial
therapy for superﬁcial keratomycoses, regardless of whether
septate hyphae or yeast cells are seen by direct microscopy;
additional antifungal agents (e.g. amphotericin B, ketoconazole,
itraconazole) are added for deep corneal infections. The initial
antifungal agent may also be chosen depending on whether
yeast cells or hyphae are seen by microscopy: if hyphae are
deﬁnitely seen by microscopy, topical natamycin (5%) is the
drug of choice (0.15% amphotericin B or, currently, 1%
voriconazole [16,17] are alternatives); if yeasts or pseudohyp-
hae are seen, topical 0.15% amphotericin B, 1% ﬂuconazole or
1% voriconazole is preferred.
Once the organism has been identiﬁed by culture, the
therapeutic regimen may be modiﬁed. Most recommendations
in the literature concerning the choice of antifungal once the
infecting fungus has been identiﬁed are probably based on
personal experience or on the results of in vitro antifungal
susceptibility testing. This led one investigator to review the
therapy of keratitis caused by frequently encountered hyaline
ﬁlamentous fungi, phaeohyphomycetes and yeast-like fungi
based on reports in the published literature [38]. Some of the
key observations made were:
 More than 70% of patients with superﬁcial keratitis due to
Fusarium solani and other Fusarium spp. apparently respond
to medical therapy alone; although several antifungals have
been found to be effective, administration of natamycin may
prevent surgical intervention. However, almost 70% of
patients with Fusarium keratitis with deep lesions do not
respond to medical therapy alone, particularly if natamycin is
not used, and some form of surgical intervention is
necessary.
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 More than 80% of patients with keratitis due to Aspergillus
ﬂavus, Aspergillus fumigatus and other Aspergillus spp. respond
to medical therapy alone with a variety of topical or systemic
antifungals; however, in the presence of deep corneal
lesions, almost 60% of patients do not respond to medical
therapy alone, particularly if natamycin is not used, and
surgical intervention is needed.
 Medical therapy of keratitis due to Candida spp. generally has
a favourable prognosis, particularly when topical amphoter-
icin B 0.15% is used alone or in combination with systemic
azoles, and the presence of deep lesions is not a major
hurdle.
 Most patients with keratitis due to Curvularia spp. can be
treated with antifungals alone, particularly when natamycin is
used; however, surgery may be required when deep lesions
are present. Keratitis due to phaeohyphomycetes other than
Curvularia spp. appears to respond to primary therapy with
topical natamycin, oral and or topical ketoconazole, oral
ketoconazole and topical miconazole, topical amphotericin B
alone or oral itraconazole alone. However, therapy of
keratitis due to Lasiodiplodia theobromae is often difﬁcult to
treat.
 Miconazole appears to be important in the treatment of
keratitis due to Scedosporium apiospermum; its rela-
tive efﬁcacy in comparison to natamycin is difﬁcult to
evaluate.
For topical therapy, most workers advise hourly application
around the clock for several days and the dosage is then
gradually reduced.
TABLE 3. Antifungal drugs to treat mycotic keratitis
Drug, features and advantages (References) Drawbacks (References)
1. Natamycin (Pimaricin)
a. Commercially available as topical 5% suspension for
ophthalmic use in some countries,
where it constitutes ﬁrst-line therapy for mycotic keratitis
b. Ophthalmic preparation is well-tolerated,
stable and can be sterilized by heat
c. Relatively high levels reportedly achieved
in cornea after topical application
a. Not commercially available as an ophthalmic preparation in many regions
b. Effective only when applied topically
c. Natamycin therapy may not be effective when keratitis is associated with deep stromal lesions
d. Only about 2% of total drug in corneal tissue is bioavailable
2. Amphotericin B
a. Good in vitro activity against Aspergillus spp. and Candida spp.;
emergence of resistant mutants rare
b. Can be administered by topical (0.15–0.30% solution),
intracameral (7.5–30 lg/0.1 mL),
intravenous (0.5–1 mg/kg BW/day) or
intravitreal (1–5 lg/0.1 mL) routes
c. Penetrates deep corneal stroma after topical application;
bioavailability sufﬁcient for susceptible fungi
Exerts direct fungicidal effect and exhibits immunoadjuvant properties
a. Intravenous administration frequently associated with renal tubular damage, due to use of
deoxycholate as vehicle
b. Subconjunctival injection causes marked tissue necrosis at the site of injection
c. Topical application of concn > 5.0 mg/mL may cause ocular irritation
(solutions of 1.5–3.0 mg/mL better tolerated)
d. Not commercially available as topical ophthalmic preparation; needs to be reconstituted from
powder or intravenous preparation
e. Poor intraocular penetration after intravenous administration
3. Miconazole
Reported routes of administration in mycotic keratitis:
topical (1%), subconjunctival
(10 mg/0.5 mL), intravenous (600–1,200 mg/day); topical and
subconjunctival administration generally well-tolerated
a. Use of intravenous preparation occasionally associated with toxicity due to the vehicle used
b. Undetectable concentration of drug in rabbit corneas and vitreous after intravenous administration
c. Generally considered useful in Scedosporium apiospermum ocular infections, but treatment failures
have occurred
4. Ketoconazole
a. Given by oral (200–400 mg/day) or topical (1–2% suspension)
routes in ophthalmic mycoses
Well-absorbed and good tissue distribution after oral
administration. Peak serum concn of 2–3
lg/mL 2–3 hours after 200 mg oral dose
a. Oral doses >400 mg/day may cause transient rise in concn of serum transaminases
b. Acid pH required for absorption
c. Prolonged administration of high doses may cause impotence, gynaecomastia or alopecia or
papilloedema. No commercially available solution of ketoconazole for topical or subconjunctival
administration in ophthalmic mycoses
5. Itraconazole
a. Synthetic dioxolane triazole
b. Given by oral (200–400 mg/day) or topical (1% suspension)
routes in ophthalmic mycoses.
Oral solution and intravenous formulation recently developed;
no reports of use in ophthalmic mycoses
c. Peak serum concn 0.3 lg/mL after single oral dose of 200 mg;
increased to 3.5 lg/mL after 200 mg/day orally for 14 days
a. Commercially available capsule (100 mg) should be taken with meal; difﬁcult to give
in infants and children
b. May be poorly absorbed after oral administration in certain groups of patients.
Caution needed in patients with previous hepatic disease
c. Absorption after oral dosing affected by antacids and H2 receptor antagonists; may interact with
other drugs
d. Poor penetration into rabbit ocular tissue, compared with ﬂuconazole and ketoconazole,
after oral dosing
e. Intravitreal injection (>10 lg) causes focal retinal necrosis in rabbits
f. No commercially available solution of itraconazole for topical or subconjunctival administration
6. Fluconazole
a. Synthetic bistriazole
Soluble in water, hence excreted through kidney; 10–20% protein
bound in serum; long half-life
b. Given by oral (50–100 mg/day), topical (0.2 to 2% solution)
or intravenous routes
c. High bioavailability, low toxicity, good stability
d. Commercially available for oral and intravenous use
a. May interact with cisapride, oral antidiabetic drugs and phenytoin after oral administration
b. Less active against Candida glabrata and Candida krusei than against C. albicans
c. May not be effective in treatment of ﬁlamentous fungal keratitis
7. Voriconazole (Azole)
a. Potent activity against a broad spectrum of yeasts and moulds
b. Oral (200 mg twice daily), topical (1%), intravenous and
intravitreal (100 μg/0.1 mL) routes of
administration have all been described
c. Achieves 53% and 38%, respectively, of plasma levels in
aqueous and vitreous following oral administration
d. Has been used successfully to treat keratitis
Voriconazole monotherapy may sometimes not effect cure; caspofungin may need to be added
Modiﬁed from ref [38]
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Voriconazole is a new generation triazole antifungal agent.
Only marketed in systemic formulation and with broad-
spectrum activity and high intraocular penetration, voriconaz-
ole has been reported to be useful in the treatment of mycotic
keratitis. In 2008, a review of the results of over 40 clinical
case reports of treatment with voriconazole led to the
suggestion that voriconazole could be safely and effectively
used against a broad range of fungal pathogens [54]. In 2010,
the authors of another review concluded that topical voric-
onazole (usually prepared from the systemic preparation, and
typically of 1% concentration) is well-tolerated by the eye and
is stable; however, they believed that additional studies were
needed to conclusively determine its efﬁcacy as a ﬁrst-line and
stand-alone treatment, preparation of higher concentrations,
and optimal dosing frequency in mycotic keratitis [55]. Table 4
summarizes the salient features of recent reports on the use of
voriconazole in therapy of clinical mycotic keratitis
[16,17,49,56–65]
Fungal keratitis usually responds slowly over a period of
weeks to antifungal therapy. Clinical signs of improvement of a
fungal corneal ulcer include a decrease in pain and in size of the
inﬁltrate, disappearance of satellite lesions, rounding out of the
feathery margins of the ulcer, and hyperplastic masses or
ﬁbrous sheets in the region of healing fungal lesions [27,66].
Signs of toxicity of the topical antifungal agent should also be
looked for. Negative scrapings during treatment do not always
indicate that the infecting fungus has been eradicated, as it may
become deep-seated; hence therapy should be maintained for
at least 6 weeks.
Although natamycin is widely used as ﬁrst-line therapy for
ﬁlamentous fungal keratitis, primary treatment failure has
been reported in 31.3% of cases in a study of 115 patients
[67]; large ulcer size, hypopyon and Aspergillus as the
causative organism have been reported as predictors of
poor outcome with topical 5% natamycin monotherapy. In
another study that compared topical voriconazole with
TABLE 4. Recent reports on voriconazole (VZ) for the treatment of mycotic keratitis
Route of administration and number of patients
[Reference] Results Microbiological data and comments
Topical 1% VZ vs topical 5% natamycin
120 patients (60 randomized to VZ,
60 randomized to natamycin)
[49]
No signiﬁcant differences in visual acuity,
scar size and perforations
between the two groups
Fusarium spp. isolated in 44 cases (21 received natamycin, 23 VZ),
different Aspergillus spp in 19 (11 received natamycin, 8 VZ) and
other ﬁlamentous fungi in 39 (21 received natamycin, 18 VZ);
however, no information provided on the organism-wise response
to either natamycin or VZ
Topical 1% VZ vs topical 5% natamycin
30 patients (15 randomized to VZ,
15 randomized to natamycin)
[17]
Complete healing in all 15 natamycin-treated
patients and 14 of 15 VZ-treated patients
Aspergillus spp. Isolated in 12 cases (6 received natamycin, 6 VZ),
Curvularia spp. in 9 (4 received natamycin, 5 VZ), Fusarium sp. in 3
(1 received natamycin, 2 VZ) and Aureobasidium in, 1 (natamycin];
no growth in culture in 5 (3 received natamycin, 2 VZ); however,
no information provided on the organism-wise response to either
natamycin or VZ
Topical 1% VZ, oral VZ (400 mg),
intracameral VZ and intrastromal VZ
26 patients (13 responded to medical
therapy alone, 11 required additional surgery)
[16]
13 cases healed
a. 7 topical VZ only
b. 1 topical VZ and 5% natamycin
c. 5 initial topical natamycin or AB,
then added topical VZ
a. Fusarium spp. isolated in 7 patients (3 responded), Candida spp. in 4
(2 responded), Scedosporium apiospermum in 3 (1 responded),
Aspergillus fumigatus in 3 (2 responded), Paecilomyces spp. in 2
(neither responded) and Bipolaris spp. in 2 (both responded)
b. Non-responders more likely to have peripheral inﬁltrates
and hypopyon
a. VZ used systemically, topically and/or
by intraocular injection
b. 24 patients (15 keratitis, 9 endophthalmitis)
Primary therapy in 8
Salvage therapy in 9
[56]
a. Overall response 67% (keratitis 73%
and endophthalmitis 56%)
b. Adjunctive surgery in 7
c. Response
Primary therapy 63%
Salvage therapy 69%
14 Fusarium solani infections, 9 (64%) responded; 8 Fusarium spp.
infections, 8 (80%) responded
69% response when VZ used in combination with topical AB,
caspofungin or natamycin) or systemic agents
64% response when VZ used alone
a. Intrastromal (50 lg in 0.1 mL) VZ
b. Topical and systemic antifungal therapy
12 patients [57]
Intracameral (50 lg/0.1 mL) and topical VZ
5 eyes (5 patients) with deep fungal keratitis
with endoexudates ( stromal inﬁltrates)
[58]
 1 intrastromal injection(s) of VZ at
junction of clear cornea and inﬁltrates
5 quadrants to form a
barrage around ulcer
In all eyes:
a. size and density of endoexudates reduced
b. complete resolution of infection
c. marked improvement in visual acuity,
within 3 weeks to 3 months
Of 12 eyes (8 with Aspergillus infection, 3 with Fusarium infection and
1 with a Curvularia infection), 10 eyes healed with scar formation
(mean resolution time was 39.75  7.62 days) and showed
improvement in visual acuity
a. The aetiological fungus could not be isolated in 3 patients
(diagnosis of fungal infection made by positive smear)
b. Aspergillus spp. were isolated from the other two eyes
a. Topical and oral VZ or topical natamycin; 3 eyes
(3 patients) all soft contact lens wearers [59]
b. Topical 1% VZ; one eye [60]
c. Topical 1% VZ and intracameral VZ;
2 eyes (2 patients) [61]
d. Topical VZ and oral terbinaﬁne; one eye [62]
a. Only one eye responded to
medical therapy alone
b. Healed within 1 month
c. One eye healed with topical VZ
alone after keratoplasty
d. Healed
a. Keratitis due to Paecilomyces species other 2 needed
other measures
b. Paecilomyces lilacinus was isolated from the ulcer (there had been
no response to topical natamycin or topical AB)
c. Paecilomyces lilacinus isolated from both eyes; the second eye
required VZ by multiple routes in addition to keratoplasty
d. Paecilomyces lilacinus recovered in culture (there had been no
response to initial topical natamycin and oral itraconazole)
a. VZ
b. caspofungin
c. natamycin
d. ﬂuconazole,
Six eyes (6 patients); two were
soft contact lens wearers [59,63,64]
a. Good response in ﬁve eyes
b. Partial response in one eye
Alternaria spp. isolated in culture
Two eyes responded well to topical and oral VZ or topical natamycin
Three eyes responded well to topical ﬂuconazole or combined VZ
(intrastromal and topical) and caspofungin
(intrastromal and topical)
Intracameral VZ
10 eyes (10 patients) with
endophthalmitis due to keratitis [65]
VZ was injected intracamerally 1 to 8 times Seven patients (6 with Fusarium and 1 with Acremonium) received 5 or
more injections
Three patients (2 with Aspergillus and 1 with Alternaria) received 4 or
fewer injections
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topical natamycin as primary therapy for mycotic keratitis,
rates of corneal perforations were 16.6% and 15% in the
voriconazole and natamycin groups, respectively [49]. The
authors did not ﬁnd any signiﬁcant differences in visual
acuity and scar size between voriconazole-treated and
natamycin-treated patients. A recent study sought to analyse
the predictors of outcome in mycotic keratitis [68]. Older
age and a larger inﬁltrate size at presentation signiﬁcantly
predicted a longer time to re-epithelialization and worsened
3-month visual acuity whereas a larger inﬁltrate size also
signiﬁcantly predicted a worsened 3-month inﬁltrate/scar
size [68]. In addition, a larger epithelial defect size was a
signiﬁcant predictor of perforation.
Surgery for mycotic keratitis
Therapeutic surgery may be required for clinical cases of
mycotic keratitis that respond poorly, or not at all, to medical
therapy, or where perforation or descemetocele formation is
imminent; however, every effort should be made to prolong
medical therapy for the maximum duration possible, to render
the infecting fungus non-viable before surgery and therein to
improve the outcome. Surgery attempts to remove antigenic
and infectious elements and also necrotic tissue and other
debris, which may hinder complete healing of the lesion.
Methods used include [27,38]:
 Debridement, tarsorraphy or superﬁcial (lamellar) keratec-
tomy (in combination with antifungal therapy) for small,
superﬁcial ulcers.
 Conjunctival ﬂap or penetrating keratoplasty for severe
keratitis that is unresponsive to medical therapy or where
serious complications supervene.
Conclusions
Although mycotic keratitis is an important, sight-threatening
problem, it has not always received the attention it deserves
from medical personnel. A silver lining of the dark cloud that
was the contact lens-associated outbreak of Fusarium spp.
keratitis in 2005–06 is that it appears to have stimulated interest
in the pathogenesis of this condition. Hopefully, this will lead to
an increase in research initiatives on this complex problem.
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